- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 17/10/2023
Further Accelerating Cell Line Development and Reducing CMC Timeline to 3 Months from DNA to IND: the Journey from COVID to Non-COVID Programs
Sam Zhang, Kee Wee Tan, Junghao Wang, Weichang Zhou
WuXi Biologics, Waigaoqiao Free Trade Zone, Shanghai, China
Since the COVID-19 outbreak, unconventional cell line development (CLD) strategies have been employed to enable development of SARS-CoV-2-neutralizing antibodies at expedited speed. In this work, we summarize the accelerated development of a total of seven antibody programs, some of which have received emergency use authorization (EUA) approval in less than two years.
This scientific poster was originally presented during the 2023 ECI Cell Culture Engineering in Cancun, Mexico
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.